by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Developing a new respiratory therapeutic requires a clear understanding of disease biology, drug activity and the evidence needed to progress a candidate through preclinical development. For pharmaceutical and biotechnology companies, accessing the right preclinical...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Choosing the right respiratory CRO (Contract Research Organisation) can be an important decision for pharmaceutical and biotechnology companies developing new treatments for respiratory disease. Preclinical respiratory research involves more than selecting an...
by Virtus | Oct 11, 2026 | Scientific Advisory Board
Professor David Jackson David Jackson, FRCP, MSc, PhD, is Professor of Respiratory Medicine at King’s College London and Clinical Director for Guy’s Severe Asthma Centre at Guy’s and St Thomas’ NHS Foundation Trust in London. Since 2024, he has also assumed clinical...
by Virtus | Oct 11, 2026 | Scientific Advisory Board
Professor Nathan Bartlett Viral Immunologist Professor Nathan W. Bartlett is a leading Australian viral immunologist with over two decades of experience translating fundamental discoveries in respiratory virus biology into clinical and industry applications. He is...
by Virtus | Sep 5, 2026 | Uncategorized
Pharmacodynamic endpoints are an important part of respiratory drug development, helping researchers understand how a therapeutic candidate affects its biological target and produces a measurable response. While pharmacokinetic studies investigate what the body does...